07:00 , Jul 5, 2010 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 1Q10 operating loss 4/7/10 TopoTarget A/S (CSE:TOPO) 17% to 40 $51.9 NA 3/31/10 Profitable Cuts are from research and preclinical development; expects annual...
07:00 , Jul 5, 2010 |  BioCentury  |  Finance

2Q approvals

2Q approvals Company Approvals Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Japan approves Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH) Amgen Inc. (NASDAQ:AMGN) FDA approves Prolia denosumab to treat osteoporosis in postmenopausal women whoare at high risk...
07:00 , May 17, 2010 |  BC Week In Review  |  Company News

Avexa infectious news

Avexa plans to reduce headcount and pursue strategic alternatives after discontinuing development of HIV candidate apricitabine. Avexa said it was unable to find a partner for the cytidine analog nucleoside reverse transcriptase inhibitor (NRTI), which...
07:00 , May 17, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Amgen Inc. (NASDAQ:AMGN) could move on Monday this week after the company announced late last Friday that it had submitted a BLA to FDA for denosumab to reduce skeletal related events (SREs) in cancer patients....
00:25 , May 12, 2010 |  BC Extra  |  Company News

Avexa discontinues apricitabine

Avexa Ltd. (ASX:AVX) plans to reduce headcount and pursue strategic alternatives after discontinuing development of HIV candidate apricitabine. Avexa said it was unable to find a partner for the cytidine analog nucleoside reverse transcriptase inhibitor...
08:00 , Jan 14, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Not applicable In vitro and in vivo studies suggest that a class of small cationic peptides called peptoids could help treat drug-resistant...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Clinical News

Apricitabine: Phase III ongoing

An independent DSMB recommended continuation of Avexa's international Phase III trial evaluating apricitabine at the 800 mg dose based on 16-week data from 3 treatment arms comparing 800 or 1,200 mg of oral apricitabine given...
07:00 , May 4, 2009 |  BioCentury  |  Finance

Ebb & Flow

If the data seem too good to be true, maybe they are. Last week, genomic testing company Sequenom Inc. (NASDAQ: SQNM) disclosed that all the data that has been publicly released for its non-invasive SEQureDx...
00:50 , May 1, 2009 |  BC Extra  |  Financial News

Avexa raises A$17 million

Avexa Ltd. (ASX:AVX) raised A$17 million (US$12.2 million) in a rights issue of 242.9 million shares at A$0.07. The price is a 22% discount to Avexa's close of A$0.09 on April 3, the record date...
07:00 , Mar 30, 2009 |  BioCentury  |  Finance

2Q09 milestones

2Q09 milestones Company Product Indication Milestone Milestone date Advanced Life (NASDAQ:ADLS) Cethromycin Community-acquired pneumonia (CAP) FDA panel 6/2/09 AGI Therapeutics (ISE:A9I; LSE:AGI) Rezular arverapamil (AGI-003) Diarrhea-predominant irritable bowel syndrome (IBS-D) Prelim Ph III data 2Q09...